Jeffrey Y.
- Country
- Sweden
- Department
- Oncology
Research Overview
- Phase 1 Evaluation of SGN-ALPV in Patients with Advanced Solid Tumors Including GEJ Carcinoma, NSCLC, Gastric, Cervical, Ovarian, and Endometrial Cancers
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
- (20289) A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors
Data & Insights
Has run more than one trial at 55 of 240 partner sites.
Specializations
Advanced Solid Tumors
The investigator specializes in treating various forms of advanced solid tumors, with particular emphasis on tumors featuring specific genetic alterations including NRG1 fusions, NTRK fusions, and BRAF alterations.
- Molecular-targeted therapies
- Genetic mutation analysis
- Personalized treatment approaches
Their research extends to novel therapeutic antibodies targeting TNFR2 and CD32b pathways.
Specialized Cancer Types
The investigator focuses on treating specific cancer types including cholangiocarcinoma, gastroesophageal junction carcinoma, and renal cell carcinoma.
- Clear cell and papillary renal cell carcinoma
- Gastrointestinal cancers
- Gynecological malignancies
Special attention is given to cases involving end-stage renal disease and advanced metastatic conditions.
Innovative Treatment Approaches
The investigator explores combination therapies incorporating immunotherapy agents with particular focus on pembrolizumab combinations and novel targeted treatments.
- Antibody-based therapeutics
- Biomarker-driven treatments
- DNA repair deficiency therapies
Research includes treatments for tumors with microsatellite instability and mismatch repair deficiency.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.